Cytek Biosciences, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Wenbin Jiang
- Full Time Employees
- 682
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 47215 Lakeview Boulevard Fremont CA United States of America 94538-6407
- IPO Date
- Jul 23, 2021
- CIK
- 0001831915
- Website
- cytekbio.com
- Similar Companies
- Business
- Cytek Biosciences, Inc. (Nasdaq: CTKB) provides cell analysis solutions leveraging proprietary Full Spectrum Profiling (FSP) technology for high-resolution, high-content, high-sensitivity analysis in life sciences research, clinical diagnostics, immunology, oncology, and infectious diseases; core products include the Cytek Aurora and Aurora Evo flow cytometers, Cytek Aurora CS cell sorter, Northern Lights systems, Cytek NL-CLC, Cytek Orion reagent cocktail preparation system, Enhanced Small Particle (ESP) detection technology, Amnis ImageStreamX imaging flow cytometer, Guava easyCyte microcapillary flow cytometer, cFluor reagents, Tonbo Reagents, Thermo Fisher Scientific reagents, beads, buffers, solutions, SpectroFlo software, and Cytek Cloud platform; services encompass training, validation, and customer support. Founded in 1992 and headquartered in Fremont, California, the company serves academic institutions, pharmaceutical and biotech firms, contract research organizations, and diagnostic labs with global operations including expanded facilities in Europe such as a new Amsterdam site opened in December 2025 to enhance EMEA presence, customer service, and training capabilities. Recent developments feature the March 2025 launch of the affordable Cytek Muse Micro cell analyzer to broaden access for smaller labs and emerging markets, a December 2024 announcement of a $50 million stock repurchase program effective January 1, 2025 through December 31, 2025 succeeding the prior program, and reaffirmed 2025 revenue guidance of $196 million to $205 million as reported in November 2025.
Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript
Cytek Biosciences Q2 Earnings Call Highlights
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates
Cytek Biosciences Reports Second Quarter 2026 Financial Results
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
Cytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026
Cytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement
Cytek Biosciences to participate at the Singular Research's Las Vegas Invitational Conference
Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026
Cytek Biosciences, Inc. (CTKB) Q1 2026 Earnings Call Transcript
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates
Cytek Biosciences Reports First Quarter 2026 Financial Results
Analysts Set Cytek Biosciences, Inc. (NASDAQ:CTKB) PT at $5.38
Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact
Cytek Biosciences Highlights Aurora Evo, Recurring Revenue Growth and 2026 Outlook at TD Cowen Conference
Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates
Cytek Biosciences, Inc. (CTKB) Q4 2025 Earnings Call Transcript
Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook